文献速递外周动脉疾病

冷冻保存静脉旁路术后抗凝未改善肢体结局

Anticoagulation does not improve limb outcomes after lower extremity cryopreserved vein bypass.
PubMed 文献 · J Vasc Surg · 2025-04-08

基于血管质量倡议(2003-2022)2336例因慢性肢体威胁性缺血行膝下冷冻保存静脉旁路的患者,比较出院时用或不用抗凝的结局。抗凝与1年通畅率、大截肢/死亡、再干预/大截肢/死亡均无显著关联,但死亡风险更低;抗血小板药物与更好结局相关。作者认为使用冷冻保存静脉时应考虑抗血小板而非抗凝。

要点

  • 抗凝与1年主要通畅丧失/死亡、大截肢/死亡、再干预/大截肢/死亡均无显著差异
  • 抗凝组1年死亡风险低于无抗凝组(HR 0.59,95%CI 0.46-0.74,P<.001)
  • 术后阿司匹林与P2Y12抑制剂均与更低的截肢/死亡及再干预/大截肢/死亡风险相关

核心结论

  • 膝下旁路使用冷冻保存静脉后,术后抗凝未影响通畅率或保肢;抗血小板药物与更好结局相关;1年总体通畅与保肢率较差。
  • 作者建议:使用冷冻保存静脉时,医生应考虑抗血小板治疗以维持冷冻保存移植物通畅,而非抗凝。

研究设计与样本

  • 回顾性队列研究,查询血管质量倡议数据库(2003-2022),纳入2336例因慢性肢体威胁性缺血使用冷冻保存静脉行膝下旁路的患者。
  • 比较出院时用与不用抗凝者的基线特征、手术细节和结局,行单变量、Kaplan-Meier和多变量分析。

主要发现

  • 平均年龄70.6岁,63.5%为男性;旁路靶血管为股/腘动脉27.5%、胫动脉72.5%;适应证为静息痛25.7%、组织缺损74.3%。
  • 出院用药:阿司匹林80.1%、P2Y12抑制剂45.6%、抗凝47.3%。
  • 抗凝组更常为静息痛(28.1% vs 23.5%)、胫动脉靶血管(78.4% vs 67.2%),较少行动脉内膜切除(27.8% vs 34.2%)(均P<.05)。
  • 1年Kaplan-Meier:抗凝组与无抗凝组主要通畅丧失/死亡为28.9% vs 34.3%,大截肢/死亡为62.3% vs 63.8%,再干预/大截肢/死亡为50.6% vs 53.8%(均P>.05);生存率抗凝组更高(85.1% vs 81.7%,P=.03)。
  • 1年多变量分析:抗凝与主要通畅丧失/死亡(HR 0.95,95%CI 0.83-1.09)、大截肢/死亡(HR 0.88,95%CI 0.74-1.05)、再干预/大截肢/死亡(HR 0.93,95%CI 0.79-1.08)均无显著关联(均P>.05),但与死亡风险更低相关(HR 0.59,95%CI 0.46-0.74,P<.001)。

关键数值与推荐

  • 术后阿司匹林与截肢/死亡风险更低相关(HR 0.74,95%CI 0.61-0.91,P=.003),与再干预/大截肢/死亡风险更低相关(HR 0.76,95%CI 0.64-0.9,P=.002)。
  • 术后P2Y12抑制剂与截肢/死亡风险更低相关(HR 0.75,95%CI 0.63-0.9,P=.002),与再干预/大截肢/死亡风险更低相关(HR 0.78,95%CI 0.67-0.91,P=.001)。
  • 在术前未使用抗凝的患者中分析,结果相似。

临床怎么用

  • 作者认为,使用冷冻保存静脉行膝下旁路时,医生应考虑抗血小板治疗以维持移植物通畅,而非抗凝。
  • 术后阿司匹林和P2Y12抑制剂的使用与更好的肢体结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cryopreserved vein grafts serve as alternative conduits for infrainguinal bypass when autogenous vein is unavailable or inadequate. Anticoagulation has been advocated to improve outcomes, but published studies demonstrate conflicting results. We assessed the association of anticoagulation on outcomes after infrainguinal bypass with cryopreserved vein in patients with chronic limb-threatening ischemia. METHODS: The Vascular Quality Initiative was queried (2003-2022) for infrainguinal bypass performed using cryopreserved vein graft for chronic limb-threatening ischemia. Baseline characteristics, procedural details, and outcomes between those discharged with or without anticoagulation were recorded. Univariable, Kaplan-Meier, and multivariable analyses were performed. RESULTS: There were 2336 patients who underwent an infrainguinal bypass with cryopreserved vein conduit. The average age was 70.6 years and 63.5% were male. Bypass targets were femoral/popliteal (27.5%) and tibial (72.5%). Indication for intervention included rest pain (25.7%) and tissue loss (74.3%). Patients were discharged with aspirin (80.1%), a P2Y12 inhibitor (45.6%), and anticoagulation (47.3%). Patients discharged on postoperative anticoagulation more often were treated for rest pain (28.1% vs 23.5%), had a tibial bypass target (78.4% vs 67.2%), and less often underwent endarterectomy (27.8% vs 34.2%) (all P < .05). Kaplan-Meier analysis at 1 year demonstrated that postoperative anticoagulation had similar freedom from loss of primary patency/death (28.9% vs 34.3%), major amputation/death (62.3% vs 63.8%), and reintervention/major amputation/death (50.6% vs 53.8%) (all P > .05), but higher survival (85.1% vs 81.7%; P = .03). Multivariable analysis at 1 year demonstrated that postoperative anticoagulation had a similar likelihood for loss of primary patency/death (hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.83.-1.09), major amputation/death (HR, 0.88; 95% CI, 0.74-1.05), and reintervention/major amputation/death (HR, 0.93; 95% CI, 0.79-1.08) (all P > .05), but a lower likelihood for death (HR, 0.59; 95% CI, 0.46-0.74; P < .001) compared with no anticoagulation. Postoperative aspirin was associated with a lower likelihood for amputation/death (HR, 0.74; 95% CI, 0.61-0.91; P = .003) and reintervention/major amputation/death (HR, 0.76; 95% CI, 0.64-0.9; P = .002). Postoperative P2Y12 inhibitor was associated with decreased likelihood for amputation/death (HR, 0.75; 95% CI, 0.63-0.9; P = .002) and reintervention/major amputation/death (HR, 0.78; 95% CI, 0.67-0.91; P = .001). Results were similar when analyzing patients who were not on anticoagulation preoperatively. CONCLUSIONS: Postoperative anticoagulation after infrainguinal bypass using cryopreserved vein did not affect patency or limb salvage. Antiplatelet agents were associated with improved outcomes. Overall patency and limb salvage rates at 1 year were poor. When cryopreserved vein is used, surgeons should consider antiplatelet therapy for cryopreserved graft patency rather than anticoagulation.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Cheng TW, Farber A, Alonso A, et al. Anticoagulation does not improve limb outcomes after lower extremity cryopreserved vein bypass. J Vasc Surg. 2025. PMID: 40209865. doi:10.1016/j.jvs.2025.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。